Reporting from the European Society of Cardiology (ESC) and European Respiratory Society (ERS) Annual Congresses 2026, Louise Bouman, Vice President of the Alliance for Pulmonary Hypertension

Louise Bouman, Vice President of the Alliance for Pulmonary Hypertension and Chair of the Dutch pulmonary hypertension foundation, attended both the European Society of Cardiology and the European Respiratory Society (ERS) Annual Congresses 2026 taking place respectively in Munich, Germany (August 28-30), and Barcelona, Spain (September 5-9). Based on the sessions she followed, she has […]

Reporting from the European Society of Cardiology (ESC) and European Respiratory Society (ERS) Annual Congresses 2026, Louise Bouman, Vice President of the Alliance for Pulmonary Hypertension Read Post »

Announcing five new “PEP Talks, part of our ongoing “Patient Empowering Patients” educational video series, September 28, 2026

We are thrilled to release five brand-new “Patients Empowering Patients” talks — five women, three countries (Italy, Turkey, the US), and five very different stories, all united by the same resilience and positive outlook that defines this community. From Aygün Mengelli Tomur’s lung transplant journey “From Waiting to Breathing: A New Beginning,” to Deger Kesimogluğlu’s

Announcing five new “PEP Talks, part of our ongoing “Patient Empowering Patients” educational video series, September 28, 2026 Read Post »

Patients and Advocates Call on US Congress to Pass Life-Changing Oxygen Reform Before End of Year

Patients, caregivers and advocates across the US are calling for passage of the SOAR Act (Supplemental Oxygen Access Reform Act), a bipartisan bill aimed at improving access to supplemental oxygen for over 1.5 million Americans with serious lung and heart conditions — including portable, high-flow liquid oxygen, which is often unreliable, delayed, or simply unavailable under current

Patients and Advocates Call on US Congress to Pass Life-Changing Oxygen Reform Before End of Year Read Post »

On 19th September, pulmonary hypertension nurses Iain Armstrong and Javier Jimenez are taking the plunge for patients for “Swim Serpentine”, covering 1,609 metres, in London’s Hyde Park

On 19th September, pulmonary hypertension nurses Iain Armstrong (Chairman of the UK pulmonary Hypertension association), and Javier Jimenez will spend one mile experiencing what their patients face every single day. They will swim in the open water of London’s Hyde Park for Swim Serpentine, covering 1,609 metres in the heart of the city. The shock

On 19th September, pulmonary hypertension nurses Iain Armstrong and Javier Jimenez are taking the plunge for patients for “Swim Serpentine”, covering 1,609 metres, in London’s Hyde Park Read Post »

The Pulmonary Vascular Research Institute (PVRI) publishes a 13-part series to help people living with pulmonary hypertension (PH), their families, and carers understand clinical trials,

This series was created by the IDDI Patient Engagement and Empowerment Workstream, of the Pulmonary Vascular Research Institute (PVRI), whose members are Hall Skaara, Louise Bouman, Jamie Myrah, Colleen Brunetti, Luke Howard, Gil Golden, Vera Toth-Fejel, Wendy Gin-Sing. The series explains what clinical trials are, how they work, and what it means to take part. All

The Pulmonary Vascular Research Institute (PVRI) publishes a 13-part series to help people living with pulmonary hypertension (PH), their families, and carers understand clinical trials, Read Post »

Multicentre study explores impaired bone morphogenetic protein receptor 2 (BMPR2) signalling across pulmonary hypertension subgroups, European Respiratory Journal Open Research 2026

A multicentre study recently published on the European Respiratory Journal Open Research looked at bone morphogenetic protein receptor 2 (BMPR2) signalling — a pathway already known to be disrupted in heritable pulmonary arterial hypertension (PAH) — across a wider range of pulmonary hypertension (PH) patients, to see whether the same disturbance shows up in other

Multicentre study explores impaired bone morphogenetic protein receptor 2 (BMPR2) signalling across pulmonary hypertension subgroups, European Respiratory Journal Open Research 2026 Read Post »

Climbing for a Cause: Krishma Kaur’s Kilimanjaro Challenge in Support of the UK Pulmonary Hypertension Association – PHA UK -and the Alzheimer’s Society

Krishma Kaur and his cousin Sean Bhaker, UK citizens, have decided to take on the challenge of climbing Mount Kilimanjaro to raise money for Alzheimer’s Society and the UK Pulmonary Hypertension Association PHA UK. All money raised will be donated directly to these two charities. Krishma and Sean have launched a Go Fund campaign to

Climbing for a Cause: Krishma Kaur’s Kilimanjaro Challenge in Support of the UK Pulmonary Hypertension Association – PHA UK -and the Alzheimer’s Society Read Post »

Inhaled pulmonary vasodilators in pulmonary hypertension: perioperative use and clinical considerations, Journal of Heart and Lung Transplant, November 2026 edition

A narrative review on inhaled pulmonary vasodilators (iPVs) in perioperative pulmonary hypertension (PH) management was published recently in Key points: Background: Pulmonary hypertension significantly raises perioperative morbidity/mortality risk, especially in cardiac and high-risk non-cardiac surgery. Traditional IV vasodilators (nitroglycerin, sodium nitroprusside) lack pulmonary selectivity and cause systemic hypotension. Established agents: The review compares five main

Inhaled pulmonary vasodilators in pulmonary hypertension: perioperative use and clinical considerations, Journal of Heart and Lung Transplant, November 2026 edition Read Post »

The Pulmonary Vascular Research Institute launches the Global PH Consult, a new, free, online service for clinicians which aims to support more equitable access to pulmonary hypertension case discussion and shared learning

The Pulmonary Vascular Research Iinstitute (PVRI’s) Access to Care Workstream has launched a new, free online service from clinicians around the world to bring anonymised complex pulmonary hypertension cases for discussion with a tailored panel of specialists. Global PH Consult is open to clinicians everywhere, with a primary focus on supporting those in low and

The Pulmonary Vascular Research Institute launches the Global PH Consult, a new, free, online service for clinicians which aims to support more equitable access to pulmonary hypertension case discussion and shared learning Read Post »

Historically Marginalized And Minoritized Populations With Pulmonary Arterial Hypertension: A Deeper Dive Into a Complex Question, CHEST July 14, 2026

In pulmonary arterial hypertension there are significant disparities in epidemiology, clinical outcomes, and healthcare access that disproportionately affect historically neglected populations, including Black Americans, Hispanic Americans, and American Indians. A State-of-the-Art review recently published on CHEST examines the disparities in the three groups. Key points: Conclusion: These disparities stem from structural/socioeconomic barriers and discrimination—not biological differences.

Historically Marginalized And Minoritized Populations With Pulmonary Arterial Hypertension: A Deeper Dive Into a Complex Question, CHEST July 14, 2026 Read Post »

The Ethical Application of Artificial Intelligence in Digital Health, European Heart Journal – Digital Health, Volume 7, Issue 6, July 2026

A recent article by Dr. Iain Armstrong and Peter Winter examines a critical blind spot in digital health ethics known as “misrecognition”, which occurs when artificial intelligence systems evaluate patients solely through easily quantifiable metrics. By prioritizing standardized data over the complex, subjective realities of living with a chronic illness, AI tools inadvertently foster epistemic

The Ethical Application of Artificial Intelligence in Digital Health, European Heart Journal – Digital Health, Volume 7, Issue 6, July 2026 Read Post »

Could sotatercept treatment be effective in patients with end-stage bronchiolitis obliterans syndrome after lung transplantation? Journal of Heart and Lung Transplant, August 2026 edition

Bronchiolitis obliterans syndrome (BOS) is the most common form of chronic lung allograft dysfunction after lung transplant, marked by progressive small airway disease with limited treatment options. This case report describes a 55-year-old woman with primary ciliary dyskinesia, post-bilateral lung transplant, who developed severe (stage 3) bronchiolitis obliterans syndrome and went into respiratory failure requiring

Could sotatercept treatment be effective in patients with end-stage bronchiolitis obliterans syndrome after lung transplantation? Journal of Heart and Lung Transplant, August 2026 edition Read Post »

Liquidia (LQDA) presents new YUTREPIA data at the US Pulmonary Hypertension Association (PHA)s International Annual conference in Dallas, June 11-14, 2026

Earlier this month, Liquidia Corporation presented four posters at the US Pulmonary Hypertension Association (PHA)’s International Conference in Dallas, sharing 24‑week ASCENT study data and broader insights on YUTREPIA (treprostinil) inhalation powder in pulmonary hypertension. Beyond clinical outcomes, the company highlighted patient‑reported cough data, the mental health strain on caregivers and the evolving role of

Liquidia (LQDA) presents new YUTREPIA data at the US Pulmonary Hypertension Association (PHA)s International Annual conference in Dallas, June 11-14, 2026 Read Post »

What’s new in pulmonary hypertension on the Knowldge Sharing Platform, May 2026

This month’s selection reflects the remarkable momentum in the pulmonary hypertension field — from landmark regulatory approvals and cutting-edge research to inspiring human stories and practical tools for patients. As always, we have curated a range of content to inform, inspire, and empower our community. RESEARCH AND SCIENCE INDUSTRY NEWS DIGITAL HEALTH AND INNOVATION TRANSPLANT

What’s new in pulmonary hypertension on the Knowldge Sharing Platform, May 2026 Read Post »

“Pulmonary hypertension and pulmonary arterial hypertension: a clarification is needed”, not a new article but still highly relevant today, ERS Editorial

This article is not new (it dates back to 2010) but we are publishing it because pulmonary hypertension (PH) and pulmonary arterial hypertension (PAH) are often confused, whereas they are very different conditions with different diagnostic approaches and treatments. Mixing them up can lead to serious diagnostic and therapeutic errors. Key points: *Pulmonary hypertension is

“Pulmonary hypertension and pulmonary arterial hypertension: a clarification is needed”, not a new article but still highly relevant today, ERS Editorial Read Post »

CalciMedica advances novel oral therapy for pulmonary hypertension, PRN Newswire, May 12, 2026

CalciMedica, a clinical-stage biopharmaceutical company, is developing CM5480, an oral CRAC channel inhibitor, as a potential first-in-class therapy for pulmonary hypertension, including pulmonary arterial hypertension. The drug targets pulmonary vascular and right ventricular remodeling, which are key drivers of disease progression in pulmonary hypertension. Preclinical studies are currently underway to evaluate its pharmacology, safety and

CalciMedica advances novel oral therapy for pulmonary hypertension, PRN Newswire, May 12, 2026 Read Post »

Diagnostic and management dilemmas in pulmonary hypertension, European Respiratory Review 2026

Despite the comprehensive, evidence-based guidance offered by current international guidelines on the management of pulmonary hypertension, clinicians frequently encounter situations where the correct diagnosis or the most appropriate treatment remains uncertain. Methods A panel of pulmonary hypertension experts identified ten real-world diagnostic and management dilemmas during 2024–2025. For each, the available evidence was reviewed and

Diagnostic and management dilemmas in pulmonary hypertension, European Respiratory Review 2026 Read Post »

Monthly roundup of content shared on the Pulmonary Hypertension Knowledge Sharing Platform – April 2026

Welcome to our April roundup of the most relevant and interesting content shared on this platform. April 2026 has been a particularly rich month, with significant news on the diagnostics, clinical trials and treatment front alongside important research on quality of life, patient preferences information, economic burden. There is also a selection of patient resources

Monthly roundup of content shared on the Pulmonary Hypertension Knowledge Sharing Platform – April 2026 Read Post »

Pulnovo Medical and Medtronic Join Forces to Advance Pulmonary Artery Denervation for Pulmonary Hypertension, Pulse 2.0, April 25, 2026

Pulnovo Medical, a Shanghai-based company developing therapies for pulmonary hypertension and heart failure, has raised $100 million in a strategic financing round led by Medtronic, which has also entered into a separate commercial agreement with the company exploring future commercialisation opportunities. Pulnovo’s flagship product is the Pulmonary Artery Denervation (PADN) System, a minimally invasive device

Pulnovo Medical and Medtronic Join Forces to Advance Pulmonary Artery Denervation for Pulmonary Hypertension, Pulse 2.0, April 25, 2026 Read Post »

TRANSLATE »
Scroll to Top